Baseline characteristics and the duration of transition period of Secukinumab treatment in moderate to severe Psoriasis.

Trial Profile

Baseline characteristics and the duration of transition period of Secukinumab treatment in moderate to severe Psoriasis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top